• Press Releases.png

    Press Releases

Pharma Medica Research Inc. Licenses OmniComm’s TrialMaster® Suite and Joins CRO Preferred Program™

February 21, 2012


Kuno van der Post Ph.D
OmniComm Systems, Inc.

Download Press Release

Fort Lauderdale, FL, February 21, 2012 – OmniComm Systems, Inc., one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace today, announced that its TrialMaster® Suite of applications has been licensed by Pharma Medica Research Inc. (Pharma Medica) to support their clients’ clinical research needs. TrialMaster, OmniComm’s flagship electronic data capture suite, is an industry leading solution with superior user experience, and interoperability.

Pharma Medica, an FDA, EMEA, and ANVISA inspected full service contract research organization servicing pharmaceutical and biotechnology companies around the world, has built a strong reputation for providing on-time performance, responsiveness to the industry, and uncompromising quality at a reasonable cost.   

“After extensive due diligence, TrialMaster came ahead as being the best fit in terms of delivering on our needs, but more importantly, the needs of our valued customers” said Pharma Medica Management.  “In addition, we are pleased to have established a partnership with an organization which shares similar business values, such as making quality the #1 priority.“

By licensing TrialMaster, Pharma Medica will be able to build, deploy, and manage complex clinical trials using OmniComm’s industry-leading electronic data capture technology. This partnership will help Pharma Medica reduce the overall clinical research costs for its clients.

Pharma Medica also joins the OmniComm CRO Preferred Program, bringing the program's membership count to close to 50 organizations. This program offers its CRO members exclusive benefits, such as a dedicated, hosted environment, sales and marketing support and training, all at a fixed price for predictability and dependability. This turnkey EDC solution allows its CRO partners to pass along the benefits of a world-class EDC solution to its customers to streamline their clinical research.

“We are pleased to have been chosen by this prestigious organization.” said Stephen Johnson, President and COO of OmniComm.  “Their client-focused approach of putting the client first mirrors our philosophy at OmniComm and we look forward to a successful partnership.”

 About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

About Pharma Medica Research Inc.

Pharma Medica Research Inc. is a full service contract research organization based in the greater Toronto area. We focus primarily on bioequivalence trials in healthy volunteers, special populations, and patients. By remaining specialized in this area, we have developed true expertise in the field. Our track record speaks for itself – we have completed over 2000 clinical trials, been successfully audited by the FDA, EMEA, and ANVISA and helped to bring over 250 drugs to markets. Through an uncompromising commitment to quality and service, a reputation for on-time performance, innovation at all levels, and delivery of services at reasonable costs, we have become trusted partners of many of the world’s leading pharmaceutical companies.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.